Pharmacyte Biotech Inc (OTCMKTS:PMCB) is one of the leading biotech firms and known for using high-tech solutions for the development of various trials focusing on cancer and other life-threatening diseases. A recently published report claims that many international oncologists seek to join hands with the company and help it develop more such drugs that can save human lives.
What Lead To This Situation
Pharmacyte always seeks for latest world-class technologies to develop drugs that can save people from cancers. This is the main reason these world-renowned industry leaders have decided to join the company.
Some of the international oncologists including the renowned laboratory & clinical investigator Dr. Manuel Hidalgo have joined the company over the past few months. A few days back, Hidalgo was named on the Scientific Advisory Board of the company. He has a proven track record in treating pancreatic cancer and many other rare and diseases.
Among others who have expressed their interest in joining the company, Dr. Daniel Von Hoff shares a special place in the biotech industry. He is actively involved in translational drug development in Scottsdale. The other big name who has expressed interest in joining Pharmacyte is none other than Dr. Matthias Löhr, who is better known for his association with Karolinska Institute in Stockholm, Sweden.
Stellar Biotechnologies Inc (OTCMKTS:SBOTD) is planning to uplist itself on NASDAQ marketplace; therefore, it has decided to execute a reverse stock split to fulfill the minimum requested criteria. As per the reports, Stellar has pledged one post-consolidated common share for every ten pre-consolidated shares trading currently.
Continuous hard work and willingness to excel in biotech field has its own rewards. According to reports, USANA Health Sciences, Inc. (NYSE:USNA) has been declared as one of the 50 fastest growing companies in the state of Utah. It’s the 8th time when USANA has made it to the Fast 50 List.
